INS-2301

Insulin Without Needles

Needle phobia is the Achilles heel of Insulin compliance. Not just for children, many adults also hate piercing their skin with an injection. InsuLife is on a mission to change this with INS-2301, an investigational medicinal skin-applied insulin.
The Future of Insulin Delivery
INS-2301 aims to be the first skin-applied Insulin. Applied directly onto the skin, INS-2301 eliminates the use of needles. The target of this breakthrough product:
  • Eliminates multiple injections per day
  • Potential for better patient compliance
  • Utilizes recombinant human insulin, a “commodity” drug product enabling cost competitiveness
Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved
cross